GO-DACT 3b 期试验:戈利木单抗联合甲氨蝶呤改善银屑病关节炎指趾炎
第 24 周时,联合组指趾炎严重度评分(DSS)中位改善 5 分,单药组 2 分(p=0.026),且联合组达到 DSS 和 Leeds 指趾炎指数(LDI)应答的比例显著更高。结论认为戈利木单抗联合 MTX 作为一线生物制剂治疗优于 MTX 单药。
要点
- 戈利木单抗联合 MTX 较 MTX 单药显著改善 PsA 指趾炎 DSS(中位降 5 vs 2 分,p=0.026)。
- 联合组达到 DSS ≥50%/≥70% 及 LDI 20%/50%/70% 改善的比例显著更高。
- 因中期分析结果有利,入组在计划招募 50% 时提前终止。
核心结论
- 戈利木单抗联合 MTX 作为一线生物制剂治疗 PsA 指趾炎优于 MTX 单药。
研究设计与样本
- 多中心、研究者发起的随机双盲安慰剂对照平行设计 3b 期试验,在葡萄牙 11 个风湿科中心开展。
- 主要终点为基线至第 24 周指趾炎严重度评分(DSS)变化,按意向治疗分析。
主要发现
- 第 24 周戈利木单抗联合 MTX 组 DSS 中位改善 5 分,MTX 单药组 2 分(p=0.026)。
- 联合组达到 DSS ≥50% 或 ≥70% 改善及 LDI 20%、50% 或 70% 改善的患者比例显著高于 MTX 单药组。
- 两组基线 DSS 中位值均为 6 分,每组各有 1 例中止治疗。
关键数值与推荐
- 主要终点为基线至第 24 周 DSS 变化。
- 关键次要终点包括 DSS 和 LDI 应答,以及 LDI 和 MRI 指趾炎评分较基线变化。
临床怎么用
- 对未用过 MTX 和生物制剂的 PsA 活动性指趾炎患者,可考虑戈利木单抗联合 MTX 作为一线生物制剂方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the efficacy of golimumab in combination with methotrexate (MTX) versus MTX monotherapy in psoriatic arthritis (PsA) dactylitis. METHODS: Multicentre, investigator-initiated, randomised, double-blind, placebo-controlled, parallel-design phase 3b trial in 11 Portuguese rheumatology centres. Patients with PsA along with active dactylitis and naive to MTX and biologic disease-modifying antirheumatic drugs (bDMARDs) were randomly assigned to golimumab or placebo, both in combination with MTX. The primary endpoint was Dactylitis Severity Score (DSS) change from baseline to week 24. Key secondary endpoints included DSS and Leeds Dactylitis Index (LDI) response, and changes from baseline in the LDI and MRI dactylitis score. Analysis was by intention-to-treat for the primary endpoint. RESULTS: Twenty-one patients received golimumab plus MTX and 23 MTX monotherapy for 24 weeks. One patient from each arm discontinued. Patient inclusion was halted at 50% planned recruitment due to a favourable interim analysis. Median baseline DSS was 6 in both arms. By week 24, patients treated with golimumab plus MTX exhibited significantly greater improvements in DSS relative to MTX monotherapy (median change of 5 vs 2 points, respectively; p=0.026). In the golimumab plus MTX arm, significantly higher proportions of patients achieved at least 50% or 70% improvement in DSS and 20%, 50% or 70% improvement in LDI in comparison to MTX monotherapy. CONCLUSIONS: The combination of golimumab and MTX as first-line bDMARD therapy is superior to MTX monotherapy for the treatment of PsA dactylitis. TRIAL REGISTRATION NUMBER: NCT02065713.
引用
- Vieira-Sousa E, Alves P, Rodrigues AM, et al. GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis. Ann Rheum Dis. 2020. PMID: 32193187. doi:10.1136/annrheumdis-2019-216500
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。